21155 ⎘
Medicinal preparations containing antigens or antibodies; Antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum Stabilisation, fragmentation
ANTIBODY-CONTAINING FORMULATION
#2FORMULATIONS WITH REDUCED DEGRADATION OF POLYSORBATE
#3Liquid Pharmaceutical Formulations for an Anti-IL-1beta Antibody
#4METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION
#5Antibody Compositions and Methods of Use Thereof
#6ROOM TEMPERATURE STABLE LYOPHILIZED PROTEIN
#7NOVEL SURFACTANTS AND USES THEREOF
#8SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF
#9PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES
#10Bispecific Molecule Stabilizing Composition
#11FORMULATIONS FOR ANTI-INSULIN RECEPTOR ANTIBODY AND USES THEREOF
#12STABLE ANTIBODY COMPOSITION
#13FORMULATIONS WITH REDUCED OXIDATION
#14ANTIBODY FORMULATIONS
#15PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES
#16PHARMACEUTICAL COMPOSITIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND rHuPH20 OR VARIANTS OR FRAGMENTS THEREOF
#17STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
#18STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
#19STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
#20Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies
#21Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies
#22PREPARATION OF POLYPEPTIDE FORMULATIONS USING VAPOR PHASE DEPOSITION
#23PHARMACEUTICAL FORMULATIONS OF FCRN INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION
#24PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES
#25ANTIBODY FORMULATIONS
#26STABLE AQUEOUS FORMULATIONS FOR ANTIBODIES
#27Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
#28TRIPLE COMBINATION CANCER THERAPY WITH ANTI-PVRIG ANTIBODIES, ANTI-TIGIT ANTIBODIES, AND PEMBROLIZUMAB
#29RISANKIZUMAB COMPOSITIONS
#30FGF21 MIMETIC ANTIBODIES AND USES THEREOF
#31ANTI-PDL1 ANTIBODY FORMULATIONS
#32STABLE FORMULATIONS FOR ANTIBODIES
#33FORMULATIONS FOR ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES
#34PHARMACEUTICAL COMPOSITIONS OF A PD-1 ANTIBODY AND USE OF THE SAME
#35REDUCING VISCOSITY OF PHARMACEUTICAL FORMULATIONS
#36COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES THAT BIND TO CLAUDIN 6 AND CD3, AND USES THEREOF
#37ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
#38USE OF SUCROSE, MANNITOL AND GLYCINE TO REDUCE RECONSTITUTION TIME OF HIGH CONCENTRATION LYOPHILIZED BIOLOGICS DRUG PRODUCTS
#39PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-HER2 ANTIBODY FOR SUBCUTANEOUS ADMINISTRATION
#40METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREBY
#41METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY
#42PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES
#43FORMULATION FOR ANTIGEN-BINDING MOLECULES THAT BIND TO PORPHYROMONAS GINGIVALIS
#44METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY
#45STABLE ANTIBODY FORMULATION
#46BIFUNCTIONAL PROTEIN, AND PREPARATION THEREOF AND USE THEREOF
#47COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SYSTEM ATROPHY (MSA)
#48PROCESS FOR REDUCING SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION
#49STABLE FORMULATIONS FOR TNF-alpha ANTIBODIES AND USES THEREOF
#50PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES
#51PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES
#52PHARMACEUTICAL FORMULATIONS OF MASKED ANTIBODIES
#53STABLE FORMULATIONS OF ANTI-ILT4 ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THEREROF IN COMBINATION WITH ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
#54HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION
#55High Concentratioin Anti-BLYS Pharmaceutical Formulations
#56PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES
#57HUMANIZED ANTIBODIES WITH INCREASED STABILITY
#58Stabilised Protein Solutions
#59ANTI-CD3 ANTIBODY FORMULATIONS
#60ANTI-EGFR ANTIBODY DRUG CONJUGATES
#61COMPOSITIONS AND METHODS OF USE
#62Anti-CD40 Antibodies for Use in Treatment of Sjogren's Syndrome
#63Antibody Compositions and Methods of Use Thereof
#64High Concentration Bispecific Antibody Formulations
#65STABLE, AQUEOUS FORMULATIONS OF ANTIBODIES THAT BIND IL5 RECEPTOR
#66ANTIBODY FORMULATION
#67PROCESS FOR REDUCING SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION
#68COMPOSITIONS COMPRISING AN ANTI-LAG-3 ANTIBODY OR AN ANTI-LAG-3 ANTIBODY AND AN ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY
#69ANTI-PDL1 ANTIBODY FORMULATIONS
#70PHARMACEUTICAL FORMULATIONS AND METHODS OF MAKING THE SAME
#71Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
#72REDUCING POLYSORBATE DEGRADATION IN PROTEIN FORMULATIONS BY LOW AMOUNTS OF CITRIC ACID
#73METHODS, COMPOSITIONS AND KITS FOR TREATING A SUBJECT USING A RECOMBINANT HETEROMULTIMERIC NEUTRALIZING BINDING PROTEIN
#74PHARMACEUTICAL COMPOSITIONS OF ANTI-IGF-1R ANTIBODIES
#75Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
#76COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES
#77ANTI-IL-31RA ANTIBODY-CONTAINING FORMULATIONS
#78PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODIES AND METHODS OF USING THE SAME
#79ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS
#80METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY
#81Stabilized Formulations Containing Anti-BCMA x Anti-CD3 Bispecific Antibodies
#82FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY
#83Pharmaceutical Product With Increased Stability Comprising Immunoglobulins
#84METHOD OF MODIFYING ISOELECTRIC POINT OF ANTIBODY VIA AMINO ACID SUBSTITUTION IN CDR
#85METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY
#86PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES
#87PROCESS FOR REDUCING SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION
#88Pharmaceutical products and stable liquid compositions of IL-17 antibodies
#89COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES
#90COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES
#91COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES
#92Methods of Controlling the Formation of Disulfide Bonds in Protein Solutions
#93HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION
#94HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION
#95Method To Control High Molecular Weight Aggregates In An Antibody Composition
#96ANTIBODY FORMULATIONS AND USES THEREOF
#97ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF
#98FORMULATIONS OF ANTIBODY MOLECULES TO DENGUE VIRUS
#99FORMULATIONS OF IMMUNE CHECK POINT INHIBITORS OR LIKE
#100Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies
#101STABLE LIQUID FORMULA
#102ANTI-FEL D1 ANTIBODY FORMULATIONS
#103METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREBY
#104HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION
#105HIGH CONCENTRATION PROTEIN FORMULATION
#106METHOD OF RECONSTITUTING LYOPHILIZED FORMULATION
#107METHODS FOR ENHANCING ANTIBODY PRODUCTIVITY IN MAMMALIAN CELL CULTURE AND MINIMIZING AGGREGATION DURING DOWNSTREAM, FORMULATION PROCESSES AND STABLE ANTIBODY FORMULATIONS OBTAINED THEREOF
#108Prevention of disulfide bond reduction during recombinant production of polypeptides
#109FORMULATION FOR ANTI-FCRN ANTIBODY
#110FORMULATIONS OF ANTI-PD1 ANTIBODIES
#111SUPERCONCENTRATED FORMULATIONS OF BIOACTIVE AGENTS
#112HIGH CONCENTRATION FORMULATION AND USES THEREOF
#113METHODS DIRECTED TO CRYSTALLINE BIOMOLECULES
#114PHARMACEUTICAL FORMULATION CONTAINING AN ANTI-IgE ANTIBODY
#115SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
#116PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTI-CD37 ANTIBODIES
#117HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS OF TREATING SUBJECTS SUFFERING FROM ATYPICAL HEMOLYTIC SYNDROME
#118Method of modifying isoelectric point of antibody via amino acid substitution in CDR
#119SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES
#120ANTIBODY COMPOSITION
#121Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
#122Method of modifying isoelectric point of antibody via amino acid substitution in CDR
#123Pharmaceutical compositions comprising anti-human TSLP receptor antibodies and methods of using the same
#124PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES
#125METHODS AND COMPOSITIONS RELATED TO ANTIBODY FRAGMENTS THAT BIND TO TUMOR-ASSOCIATED GLYCOPROTEIN 72 (TAG-72)
#126Prevention of disulfide bond reduction during recombinant production of polypeptides
#127Prevention of disulfide bond reduction during recombinant production of polypeptides
#128COMPOSITIONS COMPRISING 4-1BB and OX40 BINDING PROTEINS AND METHODS OF USE
#129Liquid Pharmaceutical Composition Comprising an Anti-IL-6 Receptor Antibody
#130Prevention of disulfide bond reduction during recombinant production of polypeptides
#131COMPOSITION AND METHODS FOR STABILIZING LIQUID PROTEIN FORMULATIONS
#132PHARMACEUTICAL COMPOSITIONS
#133HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY
#134METHODS AND COMPOSITIONS COMPRISING AN ANTI-CTLA4 MONOCLONAL ANTIBODY WITH REDUCED HOST CELL PROTEINS AND INCREASED POLYSORBATE-80 STABILITY
#135ANTI-IL-5 ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF
#136HUMAN CD3 BINDING ANTIBODY
#137ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6
#138FREEZE DRIED ANTIBODY FORMULATIONS AND METHODS THEREOF
#139ANTIBODY-DRUG CONJUGATE LYOPHILISED FORMULATION
#140COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY
#141ANTI-PVRIG ANTIBODIES FORMULATIONS AND USES THEREOF
#142Lyophilized powder configured for reconstitution as a liquid pharmaceutical formulation with reduced viscosity and method of preparing thereof
#143COMPOSITIONS COMPRISING AN ANTI-LAG-3 ANTIBODY OR AN ANTI-LAG-3 ANTIBODY AND AN ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY
#144ANTIBODY COMPOSITION
#145FORMULATIONS OF ANTIBODY
#146PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA AMYLOID ANTIBODIES
#147Compositions and methods for treating synucleinopathies
#148Anti-Interleukin-4 Receptor (IL-4R) Antibody Formulations
#149METHODS OF TREATING TUMORS
#150ANTI-TSLP ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF
#151ANTI-PDL1 ANTIBODY FORMULATIONS
#152METHOD FOR OBTAINING A COMPOSITION COMPRISING HUMAN PLASMA-DERIVED IMMUNOGLOBULIN M
#153HUMAN ANTI-IL-33 NEUTRALIZING MONOCLONAL ANTIBODY
#154METHODS OF INACTIVATING VIRAL CONTAMINANTS
#155Antibody Compositions and Methods of Use Thereof
#156FGF21 MIMETIC ANTIBODIES AND USES THEREOF
#157METHODS FOR QUANTITATING INDIVIDUAL ANTIBODIES FROM A MIXTURE
#158STABILIZED ANTIBODY PROTEIN SOLUTIONS
#159STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES
#160ANTI-RSV MONOCLONAL ANTIBODY FORMULATION
#161PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODY
#162Prevention of disulfide bond reduction during recombinant production of polypeptides
#163VISCOSITY-REDUCING EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS
#164OPTIMIZED RATIOS OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH CONCENTRATIONS OF PROTEIN-BASED THERAPEUTIC AGENTS
#165ANTI-IL-36R ANTIBODY FORMULATIONS
#166STABILIZATION OF ANTIGENS FOR LONG TERM ADMINISTRATION IN TRANSDERMAL MICRONEEDLE PATCHES
#167Prevention of disulfide bond reduction during recombinant production of polypeptides
#168METHOD OF TREATING AMYLOIDOSIS
#169PHARMACEUTICAL FORMULATIONS OF FCRN INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION
#170Pharmaceutical Formulations
#171FORMULATIONS OF ANTI-PD1 ANTIBODIES
#172ETAR ANTIBODY, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
#173ALTERNATIVE SURFACTANTS AS STABILIZERS FOR THERAPEUTIC PROTEIN FORMULATIONS
#174Stabilized Formulations Containing Anti-IL-33 Antibodies
#175HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION
#176STABLE AQUEOUS HIGH CONCENTRATION FORMULATION OF INTEGRIN ANTIBODY
#177Liquid pharmaceutical composition
#178ANTI-CD20 ANTIBODY FORMULATION AND USE OF ANTI-CD20 ANTIBODY FOR TREATMENT OF CD20 POSITIVE DISEASES
#179STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
#180FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY
#181ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS
#182ANTI-PD-L1 ANTIBODY PREPARATION
#183PREPARATION SPECIFICALLY BOUND WITH CD137 AND USE THEREOF
#184Saposin-A derived peptides and uses thereof
#185SOLUTION PREPARATION CONTAINING STABILIZED ANTIBODY
#186EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS
#187ANTIBODY FORMULATIONS
#188STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
#189Binding Members to PD-L1
#190USE OF CHELATORS FOR THE PREVENTION OF VISIBLE PARTICLE FORMATION IN PARENTERAL PROTEIN SOLUTIONS
#191LOW-VISCOSITY, HIGH CONCENTRATION EVOLOCUMAB FORMULATIONS AND METHODS OF MAKING THE SAME
#192ANTIBODY-CONTAINING FORMULATION
#193Pharmaceutical composition of a humanized anti-CD40 antibody
#194METHOD OF TREATING DISEASES USING AN IL-17 RECEPTOR ANTIBODY FORMULATION
#195ANTIBODY AND PROTEIN FORMULATIONS
#196FORMULATIONS WITH REDUCED OXIDATION
#197FORMULATION COMPRISING ANTI-IL-23P19 ANTIBODY, METHOD FOR PREPARING SAME AND USE THEREOF
#198ANTI-TNF-a ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF
#199High concentration antibody-containing liquid formulation
#200Antibody compositions
#201Novel Method For Producing Low Viscous And Highly Concentrated Biopharmaceutical Drug Products In Liquid Formulation
#202Anti-CGRP Antibody Formulation
#203PHARMACEUTICAL COMPOSITIONS COMPRISING ADALIMUMAB
#204Method Of Preparing A Therapeutic Protein Formulation And Antibody Formulation Produced By Such A Method
#205FORMULATIONS OF ANTI-ENDOTHELIAL LIPASE ANTIBODIES
#206Aqueous Formulation of Erythropoiesis Stimulating Protein Stabilised by Antioxidants for Parenteral Administration
#207Methods for quantitating individual antibodies from a mixture
#208MONOCLONAL ANTIBODY DRY POWDERS
#209Subcutaneous HER2 antibody formulations
#210PHARMACEUTICAL PACKAGE FOR OPHTHALMIC FORMULATIONS
#211PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-4R ANTIBODY AND USE THEREOF
#212Immunoglobulin Preparation and Storage System for an Immunoglobulin Preparation
#213Methods of treatment of arthritis and/or psoriasis with pharmaceutical formulations of etanercept
#214METHODS OF SEPARATING HOST CELL LIPASES FROM AN ANTI-LAG3 ANTIBODY PRODUCTION
#215Process for concentration of antibodies and therapeutic products thereof
#216STABILIZATION OF AQUEOUS COMPOSITIONS OF PROTEINS WITH DISPLACEMENT BUFFERS
#217EXCIPIENT COMPOUNDS FOR PROTEIN PROCESSING
#218Liquid pharmaceutical composition
#219PHARMACEUTICAL FORMULATIONS OF TNF-ALPHA ANTIBODIES
#220ANTI-PD-L1 ANTIBODY FORMULATIONS
#221STABLE AQUEOUS ANTI-TFPI ANTIBODY FORMULATION
#222Formulations for Enteric Delivery of Therapeutic Agents
#223METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#224Viscosity-reducing excipient compounds for protein formulations
#225EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS
#226PHARMACEUTICAL COMPOSITIONS OF A PD-1 ANTIBODY AND USE OF THE SAME
#227PROTEIN FORMULATIONS AND METHODS OF MAKING SAME
#228Stabilised Protein Solutions
#229ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMMUNOGLOBULIN AND USES THEREOF
#230EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS
#231High Concentration Bispecific Antibody Formulations
#232METHOD OF MODIFYING ISOELECTRIC POINT OF ANTIBODY VIA AMINO ACID SUBSTITUTION IN CDR
#233CRIZANLIZUMAB CONTAINING ANTIBODY FORMULATIONS
#234FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY
#235AGLYCOSYLATED ANTIBODY Fc REGION FOR TREATING CANCER
#236PURIFIED ANTIBODY COMPOSITION
#237Pharmaceutical Formulations of Bi-Specific Diabodies and Use of the Same
#238High concentration antibody-containing liquid formulation
#239ANTI-PVRIG ANTIBODIES FORMULATIONS AND USES THEREOF
#240LYOPHILIZED ANTIBODY FORMULATION
#241OPTHALMIC COMPOSITION OF BEVACIZUMAB
#242ROOM TEMPERATURE STABLE LYOPHILIZED PROTEIN
#243PROCESSES FOR OBTAINING A HIGHLY CONCENTRATED ANTIBODY SOLUTION
#244FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
#245IL-6 antagonist formulations and uses thereof
#246Antibody Compositions and Methods of Use Thereof
#247High concentration immunoglobulin composition for pharmaceutical application
#248SIALYLATED GLYCOPROTEINS
#249DRY MICROPARTICLES
#250ANTI-CD137 MOLECULES AND USE THEREOF
#251Novel Formulations Which Stabilize Low Dose Antibody Compositions
#252METHODS OF REDUCING THE ENZYMATIC HYDROLYSIS ACTIVITY RATE IN A COMPOSITION OBTAINED FROM A PURIFICATION PLATFORM
#253ANTI-IL5R ANTIBODY FORMULATIONS
#254IPILIMUMAB VARIANTS WITH ENHANCED SPECIFICITY FOR BINDING AT LOW PH
#255Anti-IL-31RA antibody-containing formulations
#256LIQUID PHARMACEUTICAL COMPOSITION
#257FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES
#258High concentration anti-blys pharmaceutical formulations
#259Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist
#260METHOD TO PRODUCE A HIGHLY CONCENTRATED IMMUNOGLOBULIN PREPARATION FOR SUBCUTANEOUS USE
#261Pharmaceutical formulations comprising anti-RANKL antibodies and an aromatic amino acid comprising a phenyl or an indole
#262FORMULATION COMPRISING ANTI-CD47 ANTIBODY, PREPARATION METHOD THEREFOR AND USE THEREOF
#263Methods of administering anti-IL31A antibody-containing formulations
#264NANOENCAPSULATION OF ANTIGEN-BINDING MOLECULES
#265ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS
#266STABILIZED RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN COMPOSITIONS
#267AQUEOUS PHARMACEUTICAL FORMULATIONS
#268Anti-CGRP Antibody Formulation
#269ANTIBODY FORMULATIONS
#270FORMULATIONS OF ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
#271PREVENTION OF PROTEIN DISULFIDE BOND REDUCTION
#272EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS
#273PREPARATION COMPRISING ANTI-PCSK9 ANTIBODY AND USE THEREOF
#274Methods of Treating Multiple Myeloma
#275FORMULATIONS WITH REDUCED DEGRADATION OF POLYSORBATE
#276Anti-IL-6 Antibody Formulation
#277Method of filling a container with no headspace
#278Stabilized Formulations Containing Anti-CTLA-4 Antibodies
#279LAG-3 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF
#280Pharmaceutical composition comprising anti-human TSLP receptor antibody
#281PHARMACEUTICAL ANTI-TNF-ALPHA ANTIBODY FORMULATION
#282HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS
#283STABLE LIQUID COMPOSITION COMPRISING PROTEIN
#284Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
#285BIOPHARMACEUTICAL FORMULATION OF ANTI-PD-1, ANTI-PD-L1, AND ANTI-VEGFR THERAPEUTIC MONOCLONAL ANTIBODIES AND METHOD FOR TREATING NSCLC BY INHALATION
#286STABLE FORMULATIONS OF THERAPEUTIC ANTIBODY
#287ACTIVIN A ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF
#288VEGF Antagonist Formulations
#289STABLE PREPARATION COMPRISING ANTI-PCSK9 ANTIBODY
#290EXCIPIENT COMPOUNDS FOR PROTEIN PROCESSING
#291METHODS OF TREATING IgA NEPHROPATHY WITH AN APRIL BINDING ANTIBODY
#292ANTIBODY FORMULATION
#293Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
#294Compositions and methods for stabilizing protein-containing formulations
#295Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
#296Stable liquid pharmaceutical formulation of anti-influenza virus antibody
#297Treatment with anti-α4β7 antibody
#298Humanized antibodies with increased stability
#299Stabilized antibody compositions
#300METHODS FOR TREATING OCULAR DISEASES